Vitasora Health Limited · ASX:VHL
Vitasora Health — Investor Presentation (March 2025)
23 slides from Vitasora Health's investor presentation, Mar 3, 2025
Slide 1: Capital Raising Presentation
Capital Raising Presentation Capital Raising to Accelerate the Commercialisation of Respiri’s Remote Patient Services in the U.S. 1
Slide 2: Important Notices and Disclaimer
Important Notices and Disclaimer Forward Looking Statements Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri’s current expectations, estimates and projections about the industry in w
Slide 3: Important Notices and Disclaimer
Important Notices and Disclaimer Section 708 Disclaimer This investor presentation has been provided to assist interested parties to make their own evaluation of Respiri and its subsidiaries (Respiri Group), and does not purport to contain all of the material information that a prospective investor
Slide 4: Executive Summary
Executive Summary • Respiri is a provider of Remote Patient Monitoring (RPM) for individuals in the U.S. with chronic health conditions • Utilises technology and Care Coordinators to monitor and collect health data from patients, which is then transmitted to Respiri Overview healthcare providers for
Slide 5: Capital Structure
Capital Structure Respiri Capital Structure Share Price Performance Last 12 Months In $ per share (index rebased) Last Traded Share Price (A$/share) $0.048 0.12 Shares Outstanding (#) 1,502 million Market Capitalisation (A$) $72.1M 0.10 Net Cash(1) (A$) $1.3M Respiri (RSH) Enterprise Value (A$) $73.
Slide 6: Investment Highlights
Investment Highlights ~6,5001 6 Respiri Patient Programs and Patient Pipeline patient programs 40 major clients in late- + Orb UPEC2 patient clients contracted stage contract Respiri forecasts services negotiations c.30% conversion of its TAM into 350,000 Patient Programs 70,000 patient3 Orb Acquisi
Slide 7: Revisiting: What Does Respiri Do?
Revisiting: What Does Respiri Do? What does Respiri do?... How does Respiri deliver RPM? Who is the target market for Remote Patient Monitoring Devices RPM? ➢ >65 years of age • Remote Patient Monitoring (RPM) ➢ Medicare insured patients refers to healthcare services delivered Clinical ➢ High-risk/h
Slide 8: Challenges Facing the U.S. Health Market
Challenges Facing the U.S. Health Market CMS budget increases vs key Why are costs increasing?... insurer cost growth in 2024 c.18% Drivers of continued cost Ageing Population pressure … • Demographic shifts are a significant driver of rising healthcare costs, as more baby boomers c.2% ➢ Growing por
Slide 9: Why Is There a Need for Remote Patient Services?
Why Is There a Need for Remote Patient Services? The current situation1 … Solution? … ~95% All of whom qualify for ~150M of individuals ages 65+ live with at least one chronic disease Medicare (and Medicaid, Remote Patient Monitoring Americans are living with at depending on income) least one chroni
Slide 10: Key Government and Industry Body Support
Key Government and Industry Body Support Summary of announcement: • CMS has mandated and made substantial progress toward its goal of having all individuals with Traditional Medicare (fee-for-service) in a care relationship that holds providers accountable for quality and total cost CMS moves closer
Slide 11: Risk Share Model – The Future of U.S Healthcare Delivery
Risk Share Model – The Future of U.S Healthcare Delivery Respiri currently derives revenue from two different models: Outcome for Respiri 1. Fee-for-service (FFS) • Respiri has been recently engaged in a pilot program for a 5,000 • The CMS provides a budget patient risk-share agreement to the health
Slide 12: Respiri's Operational Momentum is Driven by Its Unique Value Proposition
Respiri’s Operational Momentum is Driven by Its Unique Value Proposition Respiri has experienced significant acceleration in its business, with key performance indicators (KPIs) reflecting strong momentum What are the key factors behind Respiri’s Key Performance Indicators success?… 4QFY24 2QFY25 +3
Slide 13: Growth Capital Required to Accelerate Commercialisation
Growth Capital Required to Accelerate Commercialisation Management Outlook for Respiri OUTLOOK Respiri requires capital to execute NOW 12-18 months on its next stage of growth Patient Capital will be allocated to the following key areas to 6,500 30,000 Programs execute on the market opportunity and
Slide 14: Equity Raising
EQUITY RAISING 14
Slide 15: Equity Raising Summary
Equity Raising Summary • Respiri (RSH) received firm commitments for a capital raising of A$4.0 million via a placement (Placement) of fully paid ordinary shares (New Shares) Offer Size and • The Placement with investors will settle in two tranches, the first tranche of A$2.70 million (“First Tranch
Slide 16: Sources & Uses of Funds (Gross)
Sources & Uses of Funds (Gross) Sources of Funds A$M Equity Raising – Institutional Placement $4.0M Total Sources of Funds $4.0M Uses of Funds A$M Scaling clincal, sales and account management teams $2.0M Preparing for ACO/IPA contracts $0.5M Technological investment $0.3M Marketing and customer eng
Slide 17: Indicative Investor Timetable
Indicative Investor Timetable Indicative Investor Timetable Date Announce completion of Placement, trading halt lifted and recommencement of trading Monday, 3 March 2025 Settlement of New Shares under the First Tranche Friday, 7 March 2025 Allotment and expected normal trading of New Shares issued u
Slide 18: Appendix A: Key Risks
APPENDIX A: KEY RISKS 18
Slide 19: Key Risks
Key Risks This report identifies some of the major risks associated with an investment in the Company. The risk factors below ought not to be taken as exhaustive of the risks faced by the Company or by investors in the Company. 1. Regulatory & Policy Risks • CMS Reimbursement Uncertainty: Medicare r
Slide 20: Key Risks
Key Risks 4. Financial & Business Model Risks • Risk-Share Performance Variability: Revenue from ACO and IPA value-based/risk-share contracts depend on meeting cost-reduction and patient outcome targets. Variations in hospitalization rates, patient adherence, and chronic disease management costs cou
Slide 21: Key Risks
Key Risks 6.a Artificial Intelligence & Technology Risk • AI Reliability & Accuracy: The use of AI and voice recognition in patient onboarding and clinical engagement may occasionally produce inaccurate or unreliable results, potentially leading to customer dissatisfaction. • Customer Retention & Re
Slide 22: Key Risks
Key Risks 9. Future Funding Risk: • Funding Requirements: Respiri’s future capital needs depend on various factors, including marketing expenses, macroeconomic conditions, and the timing of its project pipeline. • Additional Funding Needs: The Company may require further equity or debt funding to me
Slide 23: Key Risks
Key Risks 11. General Risks: • Economic Factors: Inflation, currency fluctuations, interest rates, and supply-demand dynamics can impact operating costs and stock prices, affecting future revenues and the value of the Company’s securities, which are beyond its control. • Changes in Legislation & Reg